Lupus Management in 2015
PRESENTER: Kathryn Dao, MD
Associate Director of Rheumatology Research
Baylor Research Institute
Arthritis Care and Research Center
Dallas, TX
Credits: 0.5
Release Date: April 30, 2015
Target Audience: This activity has been designed to meet the educational needs of rheumatologists, physician assistants, and nurse practitioners involved in the care of patients with lupus.
Learning Objectives: After the completion of this activity, participants should be able to:
Summarize the management options for cutaneous lupus
Describe the benefits of hydroxychloroquine
Define the novel targets for potential new lupus therapies and the rationale for each
Physician Accreditation Statement: This activity has been planned and
implemented in accordance with the Essential Areas and Policies of the
Accreditation Council for Continuing Medical Education through the joint
providership of Purdue University College of Pharmacy and Focus Medical
Communications. Purdue University College of Pharmacy, an equal access/equal
opportunity institution, is accredited by the ACCME to provide continuing
medical education for physicians.
Credit Designation: Purdue University College of Pharmacy designates this enduring activity for a maximum of
0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement: All faculty and staff involved in the planning, review or
presentation of continuing education activities sponsored/provided by Purdue
University College of Pharmacy are required to disclose to the audience any
relevant commercial financial affiliations related to the content of the
presentation or enduring material. Full disclosure of all commercial
relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, reviewers and Focus Medical
Communications and Purdue University College of Pharmacy staff have no
relationships to disclose.
Dr. Dao has received grants and/or research support from Amgen, Celgene, Genentech, Novartis, Pfizer and UCB.